Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma has reported promising results from their Phase 2a trials of imdusiran, showing potential as a key treatment for chronic hepatitis B. The company is reshaping its strategy by focusing on the development of imdusiran and cutting down its workforce by 40% to extend its cash runway until late 2026.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
